{"name":"TxCell","slug":"txcell","ticker":"","exchange":"","domain":"","description":"TxCell was a biotechnology company focused on the development of innovative cellular immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases. The company's lead product, Ovasave, was discontinued, and the company ceased operations in 2020.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ovasave","genericName":"Ovasave","slug":"ovasave","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Ovasave","genericName":"Ovasave","slug":"ovasave","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNYmJHNXZhaDAtNkxNR2dGRGJCVlU3ekJvU2p4YlZkeXNUM0l2THFXQktyanFMWUZFTDhsVEtIWVlXZ0doM19qTWFiWEN0RFVqeEsycHRNQnN0N3p5blA5WEVDU2tFb2wxT3lmS0hfRGd1d05GSGxoekM5LXBxNnhfcjhwVG5hNTB5cVktVl9ueHdxa1hpT2ZZYlZ6VWhsR2RoaE5LT2lLT0VHNE1CWmd1Rg?oc=5","date":"2022-02-17","type":"pipeline","source":"Healio","summary":"IV vedolizumab effectively treats chronic pouchitis in UC - Healio","headline":"IV vedolizumab effectively treats chronic pouchitis in UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPU3QxN3BHSjNkRlRzQnllVF9rYzZod0tzU21JNk50MjI4dEpFZWwzTFBGTG5Rd0F3bXhqVTJqRUJsQlg4TkNJX2ZtTmNlX0xzNE02b2s2UUJ2U21IYkFuTFhxNFh1WDFSaE1aV2lvdm5fMjZ0NF9fa01ITWc5WjNHb2IwVmVvVkFmeW9jaEp4cmsyOG5MOWdKYjQxckFzdzlFaVZqTGpRR24zb2ZCVVhYRUxaVkFSZGF5UUE?oc=5","date":"2018-12-11","type":"pipeline","source":"European Medical Journal","summary":"Are We Ready to Change the Course of Inflammatory Bowel Disease? - European Medical Journal","headline":"Are We Ready to Change the Course of Inflammatory Bowel Disease?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNaWc5cUxFMHF5dFNKa2pONlFBaHgyUm5JS2hkbktYdWY4WFVNQWVRUFVtTVFmcHhiUDU5eFFzamFqeVlVV3J5bXRacVhDM3BnRjlpREtRLVE4WEs2Z0xzaFZtaU4zRkR1czIwWWJiRWZlWHlzZWIxZG5kbktPS3daa05LWVZiQWdXakF6dVA0OXhkaUJWcFFlTUVyNm9jcHAyU0MwdFI1R0prZUVzcjdTWU1n?oc=5","date":"2018-08-07","type":"pipeline","source":"SingularityHub","summary":"CAR-T May Be a Silver Bullet Against Cancer—and Here’s What Else It Can Do - SingularityHub","headline":"CAR-T May Be a Silver Bullet Against Cancer—and Here’s What Else It Can Do","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQTjFkX0lPenVsa195dC1HMTRxTGlkSGdfcE5vVmZKMEExVW13eWNQcUpTRXpBYkRtaG5YaUN0cWJBYUhET3BQVTA5X3NBNGdZS09TSW9BbWlRU0J2bmFHX2ctbmhodUx4VjU3RF9kdmxpN2lrazdYeFpfdmRKbkJOUlNVUjdsTjl2a0pTaHBtZTFUVjVTczJz?oc=5","date":"2018-07-23","type":"deal","source":"BioPharma Dive","summary":"Sangamo to buy TxCell, cell therapy tech in $84M deal - BioPharma Dive","headline":"Sangamo to buy TxCell, cell therapy tech in $84M deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQNW9ESkZRVndEM1BNQjF0dzhnemgzY3ZDcWNsMkVwTzRXOUMwN2ZzN3RIWHY4SlZTOTNUUjVhUWZHOHA3Uk1kaHNZSTZvM0YwdE9uOVB4Z09XeFJyTm9YWmdpRFJSM3FZMEhOMzRmQ2RGcnV0M3ZocERKWnZxTmkyTVNBZUZvdzhlZ1JXSFEzRlc5N0RBUUhheHhDQQ?oc=5","date":"2018-07-23","type":"pipeline","source":"Fierce Biotech","summary":"Sangamo strikes TxCell takeover to gain CAR-Treg pipeline - Fierce Biotech","headline":"Sangamo strikes TxCell takeover to gain CAR-Treg pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTFBXcXRRQktnczNwbjFIMnpPaVJvd1AtU3BzNkYzNFBBTTF5YzhiRFdWamtVcXZma1VaNDY0b3k5aF94U2Nnak0wYUZQaU5BZDV6cDVDdzlPSmxMWm9hREM3dHoxM2U4Y2hNSVMxaFJNbE5OZnM?oc=5","date":"2018-02-19","type":"pipeline","source":"Labiotech.eu","summary":"Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease - Labiotech.eu","headline":"Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOaTJjXzNQRmRWWHRwOEJEaVdsS1BpZFpZZ3pZVVFkQ21WWXh2M2FKSHlLZFFXakpiaEtJSnhVWVo2WkNvNFhEN2dwTG9obE1mdEUwMi1FR0E2U2ZVdE1xa09Ud1dnZF9ROExQRG9Wd2dlanJNRlo2ejJlWXVKWlp0d3ByWWJuUUlDX0pYNXppcFpWbUdaNDRGQ2FhdndsUHhZS0o2WW9FdFpzU3pQcnBGZGJHQVNpZw?oc=5","date":"2013-12-04","type":"pipeline","source":"News-Medical","summary":"Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell - News-Medical","headline":"Tackling orphan diseases: an interview with Damian Marron, CEO, TxCell - News","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"discontinued":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}